2025-523826-41-00招募中1 期
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
Sanofi-Aventis Recherche & Developpement1 个研究点 分布在 1 个国家目标入组 207 人开始时间: 2026年2月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 207
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Sciences and Operations
Scientific
Sanofi-Aventis Recherche & Developpement
研究点 (1)
Loading locations...
相似试验
已完成
3 期
SAR408701 versus docetaxel in previously treated, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) positive metastatic non-squamous non-small-cell lung cancer patients2024-515101-26-00Sanofi-Aventis Recherche & Developpement1
招募中
2 期
Long-term, open-label study of SAR447537 (INBRX-101) in adults with alpha-1 antitrypsin deficiency emphysema2023-508137-14-00Sanofi AATD Inc.36
招募中
1 期
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors2023-508808-38-00CDR-Life AG49
招募中
4 期
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults2025-521073-13-00Sanofi-Aventis Recherche & Developpement15
招募中
2 期
A clinical study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SB-007 in Subjects with Stargardt Disease.2024-519535-42-00Splicebio S.L.10